Ionis Pharmaceuticals Inc (NASDAQ: IONS) kicked off on Tuesday, down -0.80% from the previous trading day, before settling in for the closing price of $36.10. Over the past 52 weeks, IONS has traded in a range of $33.33-$54.44.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
While this was happening, its average annual earnings per share was recorded -33.96%. With a float of $145.54 million, this company’s outstanding shares have now reached $157.81 million.
Let’s determine the extent of company efficiency that accounts for 927 employees. In terms of profitability, gross margin is 97.3%, operating margin of -46.11%, and the pretax margin is -44.29%.
Ionis Pharmaceuticals Inc (IONS) Breakdown of a Key Holders of the stock
Our next focus will be how large-scale investors are participating in this stock of the Biotechnology Industry. The most recent insider transaction that took place on Nov 12 ’24, was worth 45,278. In this transaction EVP Research of this company sold 1,194 shares at a rate of $37.92, taking the stock ownership to the 33,713 shares. Before that another transaction happened on Nov 12 ’24, when Company’s Chief Executive Officer sold 6,630 for $38.05, making the entire transaction worth $252,294. This insider now owns 167,393 shares in total.
Ionis Pharmaceuticals Inc (IONS) Recent Fiscal highlights
According to the Wall Street analysts, stocks earnings will be around -33.96% per share during the next fiscal year.
Ionis Pharmaceuticals Inc (NASDAQ: IONS) Trading Performance Indicators
Take a look at Ionis Pharmaceuticals Inc’s (IONS) current performance indicators. Last quarter, stock had a quick ratio of 8.82. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 7.04.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -2.44, a number that is poised to hit -1.09 in the next quarter and is forecasted to reach -3.42 in one year’s time.
Technical Analysis of Ionis Pharmaceuticals Inc (IONS)
Looking closely at Ionis Pharmaceuticals Inc (NASDAQ: IONS), its last 5-days average volume was 1.15 million, which is a drop from its year-to-date volume of 1.33 million. As of the previous 9 days, the stock’s Stochastic %D was 82.34%. Additionally, its Average True Range was 1.29.
During the past 100 days, Ionis Pharmaceuticals Inc’s (IONS) raw stochastic average was set at 13.05%, which indicates a significant decrease from 48.72% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 48.47% in the past 14 days, which was higher than the 40.83% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $37.95, while its 200-day Moving Average is $42.44. However, in the short run, Ionis Pharmaceuticals Inc’s stock first resistance to watch stands at $36.19. Second resistance stands at $36.56. The third major resistance level sits at $37.06. If the price goes on to break the first support level at $35.32, it is likely to go to the next support level at $34.82. Now, if the price goes above the second support level, the third support stands at $34.45.
Ionis Pharmaceuticals Inc (NASDAQ: IONS) Key Stats
The company with the Market Capitalisation of 5.65 billion has total of 157,897K Shares Outstanding. Its annual sales at the moment are 787,650 K in contrast with the sum of -366,290 K annual income. Company’s last quarter sales were recorded 133,810 K and last quarter income was -140,480 K.
